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Aims Whether adjusting interventricular (VV) delay changes haemodynamic efficacy of cardiac resynchronization therapy
(CRT) is controversial, with conflicting results. This study addresseswhether the convention for keeping atrioventricular
(AV) delay constant during VV optimization might explain these conflicts.
Method
and results
Twenty-two patients in sinus rhythm with existing CRT underwent VV optimization using non-invasive systolic blood
pressure. Interventricular optimization was performed with four methods for keeping the AV delay constant:
(i) atrium and left ventricle delay kept constant, (ii) atrium and right ventricle delay kept constant, (iii) time to the first-
activated ventricle kept constant, and (iv) time to the second-activated ventricle kept constant. In 11 patients this was
performed with AV delay of 120 ms, and in 11 at AV optimum. At AV 120 ms, time to the first ventricular lead (left or
right) was the overwhelming determinant of haemodynamics (13.75 mmHg at +80 ms, P, 0.001) with no significant
effect of time to second lead (0.47 mmHg, P ¼ 0.50), P, 0.001 for difference. At AV optimum, time to first ventricular
lead again had a larger effect (5.03 mmHg, P, 0.001) than time to second (2.92 mmHg, P ¼ 0.001), P ¼ 0.02 for difference.
Conclusion Time to first ventricular activation is the overwhelming determinant of circulatory function, regardless of whether this is
the left or right ventricular lead. If this is kept constant, theeffect of changing time to the secondventricle is small or nil, and
is not beneficial. In practice, itmaybe advisable to leaveVVdelay at zero. Specifying howAVdelay is kept fixedmightmake
future VV delay research more enlightening.
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Introduction
The advent of cardiac resynchronization therapy (CRT) marked a
step change improvement in the care of eligible heart failure patients,
providing a powerful reduction in morbidity and mortality.1 Cardiac
resynchronization therapy permits the clinician to adjust the relative
timing of left and right ventricular leads, i.e. the interventricular (VV)
delay. Some investigators have reported a large haemodynamic effect
of VV delay adjustment, sometimes matching the size of the effect
of atrioventricular (AV) delay adjustment2–4 while others have
reported a substantially smaller effect.5
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In this study, we explored whether this disagreement between
groups could be explained by differences in convention on how
exactly AV delay is kept constant while VV delay is adjusted.
Traditionally, optimization of pacemaker timing is divided into AV
optimization and VV optimization. The reality is that the two are
intertwined, and how the two are related is rarely discussed in
detail in studies of VV optimization. When an offset is introduced
between the right ventricle (RV) and left ventricle (LV) in a VV opti-
mization, not only is there an adjustment of the timing between the
ventricles, but there will also be an obligatory change in an element
of the AV delay: either the atrium and the RV (A-RV) or the timing
between the atrium and LV (A-LV). Depending on how the protocol
is planned, either A-RV or A-LV must change during VV delay opti-
mization despite the intention to keep AV delay constant (Figure 1).
Unfortunately, this matter initially seems minor and accordingly
has not received focused attention in the many studies of VV opti-
mization. Consequently, studies have differed in their approaches
for fixing the AV delay while varying VV delay.2,6,7 For example, in
some studies the A-LV timing was kept constant at the AV
optimum, and VV adjustment was done solely by changing A-RV
timing.2,7 The reverse is also described with A-RV kept constant.8
In another common approach, the time between atrium and first
paced ventricle is kept constant and VV adjustment was done by
varying the time to the second ventricle;9,10 which ventricle is first
and which is second depends on the sign of the interventricular
delay, e.g. an AV delay of 120 ms and an interventricular delay of
40 ms (LV first) would mean the A-LV is 120 ms and the A-RV
160 ms, while in contrast an interventricular delay of 40 ms
(RV first) would mean the A-LV is 160 ms and the A-RV is 120 ms.
Many authors, including our group in the past,2,5 did not consider
the distinction important and therefore did not report their choice of
convention.5
It is not known whether the choice of convention for keeping
AV delay constant determines the magnitude of the haemodynamic
response to adjusting VV delay.4,11
This study explores the effect of different choices of what is kept
constant during a VV optimization. We do this by presenting data
showing VV optimizations by each of four possible conventions:
† Keeping A-RV constant and adjusting the A-LV;
† Keeping A-LV constant and adjusting the A-RV;
† Keeping time from atrium to the first paced ventricle constant
(LV or RV) and adjusting the time to the second ventricle (one
of themore commonly reported approaches to VVoptimization);
† Keeping the time to the second ventricle constant while adjusting
time to the first ventricle.
Methods
Study participants
Twenty-four patients in sinus rhythm with a previously implanted biven-
tricular pacemaker or defibrillator were enrolled from a single centre.
Two of the enrolled patients were unable to undergo the protocol due
to the onset of diaphragmatic capture in one, and occurrence of frequent
ventricular salvos in the other. The remaining 22 patients were able to
undergo the protocol. All results for all of these patients are shown,
and raw data are available from any author.
All 24 patients provided written consent. All procedures and proto-
cols received prior approval from the local research ethics committee
and comply with the Declaration of Helsinki.
Interventricular optimization protocol
After the first 11 patients’ data were analysed, it was evident that there
was a consistent pattern but internal review threw up the concern that
the fixed AV delay used, although a common factory nominal value,
was likely to be shorter than most patients’ physiological optima. It was
therefore decided to collect data from a further 11 patients but use for
each patient an AV delay identified individually as haemodynamically
optimal. No patients had the protocol run at two AV delays because
this would require a very lengthy recording session.
For the first 11, VV delaywas optimizedwithAVdelay kept constant at
a nominal value of 120 ms (using four different conventions for keeping
AV delay constant). For the second 11, we first performed AV delay
optimization and then conducted the study keeping AV delay fixed at
the patients’ individual AV delay optimum.
The VV optimization protocol5 consisted of alternations in VV delay
between 0 ms and the tested delay (20 ms increments between 280
and 80 ms) on a repeated basis for each tested delay (Figure 2). Non-
invasive blood pressure monitoring (Finapres Medical Systems) was
carried out continuously and the change in blood pressure was
defined as the increment from the 7 beats immediately before transition
to the 7 beats immediately after transition. We took several steps to
minimize the impact of inherent beat-to-beat variability on our
results. First, the study was performed at an atrial paced rate of
90–100 bpm to maximize the signal-to-noise ratio.12 Each transition
in each patient was repeated 16–20 times so that the effect size could
be quantified with a small standard error within that individual.13 Our
laboratory has focused on systolic blood pressure because it is simple,
can be measured invasively or non-invasively, and had the best combin-
ation of characteristics in our previous study of efficiency and reprodu-
cibility.14 All data are shown and all raw data are available from the
authors unconditionally.
Interventricular optimization was performed using four different
conventions for how AV delay is kept constant (Figure 1):
(1) Interventricular optimization with constant A-LV: Adjusting delay
between the LV and RV while keeping the timing from the atrial
lead to the LV lead is constant (120 ms for the first 11 patients, or
the AV optimum for the second 11).
What’s new?
† Vastly different haemodynamic effects are seenwith interven-
tricular (VV) optimization depending on the method used to
keep the atrioventricular (AV) delay constant (e.g. keeping
the time from atrium to the LV constant during the VV
optimization).
† It illustrates in detail why dramatically different results will be
reported by investigators using different approaches.
† Future studies addressing VV optimization should specify
exactly how AV delay is kept constant.
† Thesedata suggest that thegreatesthaemodynamic increment
comes from setting the time to the first ventricular lead.
Setting the time to the second ventricular lead to be different
to this (i.e. later) in almost all cases does not improve haemo-
dynamics and in many cases worsens it.
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(2) Interventricular optimization with constant A-RV: Adjusting delay
between the LV and RV ensuring that the timing from the atrial
lead to the RV lead is constant (120 ms or AV optimum).
(3) Interventricular optimization by only lengthening: Keeping the delay
from the atrium to the first ventricular lead constant (at 120 ms or
AV optimum) while delaying either the LV or the RV lead.
(4) Interventricular optimization by only shortening: Keeping the delay
from the atrium to the second ventricular lead constant (at 120 ms
or AV optimum) while activating either the LV or RV lead earlier.
This has never been proposed as a convention for optimization,
but we included it for analytical completeness.
In this report, when describing VV delay, positive represents RV first, and
negative represents LV first.
The second group of 11 patients underwent the preparatory step of
AV optimization so that the fixed AV delay used for them would be
their own individual AV optimum. The AV optimization process was by
our standard protocol.12
Owing to differences in terminology between the different manufac-
turers, two different protocols are required to allow the A-LV or A-RV
time to be kept constant. These are described in the Supplementary
material online,Methods.
Analysis and statistics
Data were analysed using Matlab (MathWorks) and Microsoft Excel
(Microsoft). To test whether adjusting VV delay produced a statistically
significant difference in blood pressure compared with VV0 we used a
two-tailed paired t-test. A P value of ,0.05 was considered statistically
significant. Power calculations are described in the data supplement.
Results
Adjusting AV delay showed a curvilinear change in SBP (all data from
all patients are shown in left panels of Figures 3 and 4). The mean AV
optimum(during atrial pacing) in the groupof 11patientswhohad the
VV adjustment carried out at AV optimum, was 200 ms (SD 29 ms,
range 160–250 ms). The first and second groups of 11 patients had
similar characteristics (Supplementarymaterial online, Table S1). Par-
ticipants had a mean age of 66 years (SD 8, range 54–82), QRS dur-
ation of 162 ms (SD 24 ms, range 132–220 ms), LV end diastolic
diameter 5.7 cm (SD 1.2 cm, range 4.2–9.2 cm). Other patient char-
acteristics are described in Table 1.
Haemodynamic changes are produced
by changes in atrioventricular delay
rather than by offset between ventricular
stimuli, when interventricular delay is
adjusted close to an atrioventricular
delay of 120 ms
At AV 120 ms, adjusting the time to the first ventricular lead had a
large haemodynamic effect, regardless of whether this was located
in the left or right ventricle (Figure 5, fourth column; Table 2). In con-
trast, adjusting the time to the second ventricular lead had no detect-
able haemodynamic effect, regardless of whether this was the left or
right ventricle (Figure 5, third column).
Viewing the ventricles individually, adjusting A-LV keeping A-RV con-
stant (Figure5, secondcolumn),oradjustingA-RVkeepingA-LVconstant
(Figure 5, first column), both had an effect which was composed of two
asymmetricalhalves:onehalfwhereoneventricle’sAVdelay is shortened
and theotherhalfwhere theother ventricle’sAVdelay is lengthened (AV
delay to first paced ventricular lead remained constant at 120 ms).
Among these, the only half that caused substantial change in pressure
was the shortening of an AV delay, regardless of whether this was
by shortening A-RV or A-LV. In contrast, the half which involved
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Figure1 Four conventions for VVoptimization. This sketch conceptualizes the four different potential conventions forwhat aspect of AVdelay is
kept constant during VV optimization (time from atrial activation to ventricular activation). On the vertical axis, change in relevant AV delay is
represented (this could be to the LV, RV, or first, or second ventricle paced). The horizontal axis represents VV delay, with LV paced first to the
left and RV paced to the right. The left panel shows the A-LV being kept constant while the A-RV is varied. The second panel (Boston Scientific
convention) shows the converse. The third panel (Medtronic and St JudeMedical convention) shows the time to the first ventricular lead kept con-
stant. The right panel shows the time to the second ventricular lead kept constant which is unlikely to be clinically meaningful, but is presented for
completeness.
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lengthening the delay in one ventricle produced no significant effect on
blood pressure regardless of whether it was the LV or RV lead that
was delayed.
The full pattern of all data in each individual patient is shown in
Figure 3. This involves showing each data point twice so that the
answer to each research question can be seen clearly.
Reference (VV 0) Reference (VV 0)
10 seconds
... carried out 10 times to produce 20 replicate measurements of this VV delay.
The above process is repeated for each VV delay
LV first by 80 LV first by 60 LV first by 40 LV first by 20
RV first by 20RV first by 40
All the above processes are then repeated with
a different convention for keeping AV delay constant
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Figure2 Structureof protocol. Themeasurement protocol involved a large numberof repeatmeasurements tominimize the impactof biological
noise. The fundamentalmeasurement is of the change in systolic pressurewhen the setting is changed fromreferenceVVdelay (0 ms) to a testedVV
delay. This change can also be measured on the reverse transition, recognizing that its sign should be reversed. The top panel shows two such mea-
surements of a single tested setting, 80 ms. The second panel shows how10 repeats of this produce 20 replicates for one tested VV delay. The third
panel shows that the entire process is then conducted for each other testedVV delay. The bottompanel shows that all the processes above are then
repeated for a different convention for keepingAV delay constant. In practice, it is only necessary to study two conventions (A-RVfixed, A-LV fixed)
since combinations of these produce all the settings that will be obtained by the other two conventions.
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Figure 4 Interventricular optimization in all 11 patients optimized from AV optimum. The panels are organized in the same way as Figure 3.
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Time from atrium to first ventricular lead
has a greater haemodynamic impact than
time to second ventricular lead, at
atrioventricular optimum
In contrast, at AV optimum (Figure 4), the time to the first ventricular
activation was no longer the sole determinant of pressure and the
second ventricular lead timing was no longer unimportant. Both made
a contribution (5.03 mmHg at 80 ms, P, 0.001 and 2.92 mmHg at
80 ms, P¼ 0.001, respectively) but with the first lead more important
than the second lead (P¼ 0.02). Viewing the ventricles individually,
adjusting the A-LV keeping the A-RV constant (Figure 5, second
column), or adjusting the A-RV keeping the A-LV constant (Figure 5,
first column) generally reduced bloodpressure. Therewas no evidence
that when the AV delay was optimal, a statistically significant increase in
blood pressure could be obtained fromadjusting VVdelay away from0.
Discussion
This study shows profoundly different responses to VV adjustment
when different conventions are applied for keeping the AV delay
constant, and may explain the discrepancy between the findings
from different laboratories studying VV optimization. Second, it indi-
cates that the AV delay chosen can impact on the responses to VV
adjustment. Third,with precisemeasurements for individual patients,
it suggests that almost always a VV delay of 0 is suitable. Notably, in
order to measure these changes with confidence it was necessary
to make numerous replicate measurements to allow the subtle
effects of pacemaker timing adjustment to be identified from
biological beat-to-beat variability.
Contribution of interventricular
adjustment to the physiological
benefit of biventricular pacing
Our data indicate that near an AV delay of 120 ms, the time between
atrial activation and the first ventricular activation is the overwhelming
determinant of acute haemodynamic response. When time to first
ventricular activation is kept fixed at 120 ms, there is no detectable
incremental benefit of varying the time (or choice of lead) for the
second ventricular activation.
At an optimized AV delay, too, VV delay of zero continues to
perform best. Shortening or lengthening of the A-LV appears detri-
mental. Shortening of the A-RV appears significantly detrimental,
while lengthening of the A-RV shows only a non-significant trend
to detriment. This non-significant trend could be due to intrinsic con-
duction through the right bundle branch at such long AV delays, and
hence a shorter ‘effective A-RV’ time at the longer programmed
A-RVtimes. Inotherwords, theeffectiveVVdelay11maynotbe chan-
ging as the programmed A-RV time is increased in this particular
group, and sovery little change in blood pressurewould be expected.
Atrium and left ventricle delay optimization may be of particular
importance, as any deviation from this seems to lead to detriment.
These data also suggest that the impact of changing VV may be
quantitatively different depending on whether it is assessed at short
AV delays such as AV 120 ms, or near the AV optimum. This is rele-
vant because if investigators chose the ‘only lengthen’ convention
(default in many devices), then if they conducted studies at AV
120 ms, for example, they would likely find that any VV delay
change (i.e. lengthening of A-LV or A-RV) would have no detectable
effect. This would be because the 120 ms time to first activation is
sufficiently short thatno amountof delayof the second lead could sig-
nificantly ameliorate the situation. In these circumstances, it would
only be at longer AV delays, nearer the AV optimum, that it might
be possible to detect the subtle deterioration arising from delaying
one lead or the other.
Whymight timeto thefirstpacedventricle
have the greatest haemodynamic impact?
AcutehaemodynamiceffectsofAVdelayadjustmentwerewell docu-
mented before the adventofCRT.15Our data highlight that a delay to
the first ventricular lead that is shorter than optimal (120 ms during
atrial pacing in our case) gave the same haemodynamic limitations re-
gardless of whether the other lead was activated at the same time or
later, and regardless of whether this was the LV or RV lead.We infer
from this that programming a time for filling that is shorter than the
ideal is so disadvantageous that no manipulation of the lag between
the ventricular walls, or the order of the two walls, or of choice of
which of thewalls is responsible for the early initiation of contraction
is able to significantly alleviate the haemodynamic harm. The magni-
tude of this adverse haemodynamic impact of changing from A-LV
120, A-RV 120 either to A-LV 40, A-RV 120 or to A-RV 40, A-LV
120, was 14 mmHg (P, 0.001), i.e. a highly undesirable drop in
blood pressure that would be anticipated to equate to a reduction
in cardiac output of .10%.
In contrast, when the AV delay is brought to its optimum (during
which A-LV and A-RV are kept equal) then no subsequent change
in VV delay, be it shortening or lengthening of either A-LV or A-RV,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Patient characteristics
N %
Male 19 86
ECG morphology
LBBB 16 73
RBBB 3 14
CHB 3 14
NYHA class
II 15 68
III 7 32
Device Type
CRT-D 11 50
CRT-P 11 50
Heart failure aetiology
Ischaemia 13 59
Non-ischaemic 9 41
Beta blocker 16 73
ACE-I/ARB 19 86
Aldosterone antagonist 13 59
Diuretic 14 64
LBBB, left bundle branch block; RBBB, right bundle branch block; CHB, complete
heart block; NYHA, New York Heart Association; ACE-I, angiotensin converting
enzyme inhibitor; ARB, angiotensin receptor blocker.
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is consistently able to deliver higher blood pressures; in fact, many
such changes significantly reduce blood pressure. An 80 ms pre-
activation or post-activation of either lead caused blood pressure
to fall by 3–4 mmHg (statistically significant for all combinations
except delayed activation of the RV lead).
Size of effect of interventricular delay
adjustment
Except for interventricular delay adjustments that were achieved
by shortening AV activation times to less than the already short
time of 120 ms, the adjustments had effects on blood pressure
that were small in absolute terms, of the order of 1–4 mmHg
which is probably equivalent to a 1–4% change in cardiac output.
Small changes are not necessarily clinically unimportant. The pre-
ssure increment achieved from CRT itself is of the order of
5–8 mmHg according to measurements made acutely at the time
of implant16 and over the longer term according to the COMPAN-
ION and CARE-HF data,17,18 so a change in timings that reduces
blood pressure by 1–4 mmHg should not be assumed to be trivial.
However, detecting such changes reliably is not easy because there
are spontaneous beat-to-beat changes in blood pressure and
stroke volume that are much larger than 1–4% and therefore
there is a great risk that such biological variation is mistaken for
the effect of VV delay adjustment. If this signal-to-noise problem
is not carefully considered quantitatively at the time of protocol
design,19 –21 then an optimization process might actually turn out
to be little different to a process of selecting randomly between
different pacemaker settings.13
Should interventricular delay always
be kept at 0 ms?
Thesefindingshave implications forpacingprotocols and inparticular
whether VV optimization should be performed at all. Participants in
clinical trials ofCRTwho showed aprognostic benefit underwentAV
optimization, but not VVoptimization.17,18 A recentmeta-analysis of
VVoptimization vs. empiric settings similarly showednobenefit from
VV optimization.6While this could have been due to difficulties with
study powerorVVoptimization protocol, our high precisionhaemo-
dynamic data presentedhere suggest thatonceAVdelay is optimized,
an interventricular delay of zero might be very suitable with little to
gain (and possibly something to lose) by adjusting it away from zero.
Why different studies might report
conflicting effects of interventricular
delay adjustment
Our data suggest that the phrase ‘keep AV delay fixed and adjust VV
delay’ is not a sufficiently clear description when we are describing a
VV optimization protocol. Three different interpretations of this
could each be argued to be correct: keep time to first ventricular
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Figure 5 Mean impact across all patients on haemodynamic response optimizing from AV 120 ms (upper panel) or AV optimum (lower panel).
The vertical axes represent relative systolic blood pressure comparedwith a setting of VV0. The horizontal axis represents VV delay, with a negative
value indicating the LV is paced before the RV, and a positive value indicating the LV is paced after the RV. Themean relative systolic blood pressure is
averaged for all the participants using the four different methods of VV optimization. *Settings with a significant difference (P, 0.05) in pressure
compared with VV0. Grey indicates the time to the first ventricular lead is kept constant. The outlines at the top are sketches of how time from
atrium to first ventricle changes with VV delay using the four different conventions.
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Table2 Impact of choice of convention formaintainingAVdelay, onhaemodynamic responses toVVadjustmentwhenoptimizing fromAV120 ms (upper panel) and
AV optimum (lower panel)
VV
offset
(ms)
A-RV optimization A-LV optimization Only lengthen Only shorten
FVL time
(ms)
Mean
SBPrel
(mmHg)
SE P value FVL time
(ms)
Mean
SBPrel
(mmHg)
SE P value FVL
time
(ms)
Mean
SBPrel
(mmHg)
SE P value FVL time
(ms)
Mean
SBPrel
(mmHg)
SE P value
VV optimization with an AV delay of 120 ms
280 120 20.73 1.31 0.59 40 213.45 2.84 0.003 120 20.73 0.59 0.59 40 213.45 2.84 0.003
260 120 0.25 0.69 0.72 60 22.81 0.50 0.11 120 0.25 0.72 0.72 60 22.81 0.50 0.11
240 120 0.79 0.55 0.18 80 24.41 0.95 0.0009 120 0.79 0.18 0.18 80 24.41 0.95 0.0009
220 120 0.63 0.49 0.22 100 21.96 0.45 0.002 120 0.63 0.22 0.22 100 21.96 0.45 0.002
0 120 0.00 0.00 120 0.00 0.00 120 0.00 120 0.00 0.00
20 100 22.88 0.65 0.0013 120 0.37 0.42 0.40 120 0.37 0.40 0.40 100 22.88 0.65 0.0013
40 80 26.59 1.02 0.0001 120 20.10 0.45 0.83 120 20.10 0.83 0.83 80 26.59 1.02 0.0001
60 60 216.37 0.72 0.03 120 20.84 0.54 0.15 120 20.84 0.15 0.15 60 216.37 0.72 0.03
80 40 214.05 2.69 0.002 120 20.24 0.60 0.70 120 20.24 0.70 0.70 40 214.05 2.69 0.002
VV optimization with an optimized AV delay
280 AVOpt 22.35 1.37 0.13 AVOpt-80 25.41 1.02 0.001 AVOpt 22.35 1.37 0.13 AVOpt-80 25.41 1.02 0.001
260 AVOpt 21.91 1.06 0.11 AVOpt-60 23.71 1.01 0.01 AVOpt 21.91 1.06 0.11 AVOpt-60 23.71 1.01 0.01
240 AVOpt 21.76 0.84 0.06 AVOpt-40 22.19 0.88 0.03 AVOpt 21.76 0.84 0.06 AVOpt-40 22.19 0.88 0.03
220 AVOpt 20.24 0.52 0.65 AVOpt-20 20.03 0.82 0.98 AVOpt 20.24 0.52 0.65 AVOpt-20 20.03 0.82 0.98
0 AVOpt 0.00 0.00 AVOpt 0.00 0.00 AVOpt 0.00 0.00 AVOpt 0.00 0.00
20 AVOpt -20 20.52 0.61 0.42 AVOpt 20.20 0.67 0.78 AVOpt 20.20 0.67 0.78 AVOpt-20 20.52 0.61 0.42
40 AVOpt -40 21.02 0.80 0.23 AVOpt 21.24 0.50 0.03 AVOpt 21.24 0.50 0.03 AVOpt-40 21.02 0.80 0.23
60 AVOpt -60 22.96 0.83 0.006 AVOpt 22.72 0.99 0.02 AVOpt 22.72 0.99 0.02 AVOpt-60 22.96 0.83 0.006
80 AVOpt -80 24.69 0.78 0.0002 AVOpt 23.37 0.83 0.003 AVOpt 23.37 0.83 0.003 AVOpt-80 24.69 0.78 0.0002
Themean relative systolic blood pressure across the cohort of participants is tabulated and tested for a significant difference to zero.Only when there is a change in the time to the first paced ventricle is a significant difference seen.Once there is no
longer a change in time to first paced ventricle, the difference attenuates or disappears. The first column lists the VVoffset (negativemeans LV activated first; positivemeans RV activated first). The four columns list the response to the four different
conventions with the time to first ventricular lead listed with each convention and average BP response. The P values are comparisons against VV0. FVL time, time to first ventricular lead; SBPrel, relative systolic blood pressure; SE, standard error;
AVopt, optimal AV delay.
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lead fixed and adjust time and choice of second ventricular lead5;
keep A-RV fixed and adjust A-LV2; keep A-LV fixed and adjust
A-RV.7 These three produce completely different haemodynamic
patterns. Purely for systematic completeness, there is a fourth
based on keeping the second ventricular lead fixed but this would
never be clinically suggested.
Studies keeping the first ventricular lead fixedwill find symmetrical
effects of delaying the second lead regardless of whether it is LV or
RV. If conducted at short AV delays, the researcher may find that
the effects are very small indeed. In contrast, studies keeping A-LV
or A-RV fixed might find a substantial effect, especially for the
offsets that make one of the leads activate much earlier than the
AV optimum.
Studies reporting apparently contradictory effect sizes of VV opti-
mization may therefore, after all, not be contradictory.
Study limitations
This experiment used a prolongedprotocol ofmany replicateswithin
each patient, and was specifically designed to detect differences in
their haemodynamic implications of different definitions of AV and
VV delay. This experimental protocol is designed to deliver high pre-
cision 20,21 but is not intended as routine clinical practice.
For two reasons, we studied only immediate effects on pressure.
First, with time, pressure tends to drift from its baseline value
(in different directions on different occasions in a pattern called a
random walk) that causes distributions of pressure changes within
individual patients to become wider and thereby impair the power
of a study to address a question reliably. Second, separate from the
random walk, the pressure increment from a change in AV delay
tends to reduce after a few seconds because of reflex vascular
compensation.22
We studied only 22 patients, and only at a single centre. However,
we did not select them for any baseline characteristic other than
described in the Methods section. We therefore expect that if our
study was re-conducted independently using similar methods, the
same results would be obtained.
Unfortunately we do not have data on lead position, nor on
whether the leads were considered to be optimally positioned
which has been reported to be important.23 We are hoping that
our sample of 22 patients, drawnwithout selection fromCRT recipi-
ents in our institution, cover a typical spectrum of optimality of lead
position. The pattern of haemodynamic results is similar across all
patients that might suggest that the predominant driver is delay
between atrium and first ventricular activation and not the precise
position of the LV lead.
Our study does not distinguish CRT recipients into responders vs.
non-responders, because our hospital no longer makes this distinc-
tion. Most of what is observed in clinical response is not the result
of pacing24,25 and most of the change in imaging measurements in in-
dividualCRTrecipients alsooccurs in controls26whodonotundergo
CRT pacing and is therefore, for the purposes for evaluating the
effect27 of CRT, noise. The haemodynamic responses measured in
this study were measured with high precision but even still there is
no possibility of them being strongly correlated with current mea-
sures of response except by chance.26
At the longerAVdelays, the rangeofVVdelays that couldbe tested
was occasionally limited by safety settings on the device that
prevented the full planned range being tested. The individuals in
whom this situation arose is visible in the full data disclosure in
Figures 3 and 4.
All the measurements were performed at rest. We do not know
whether the results would be similar during exercise. The beat-to-
beat variability introduced by performing exercise during the proto-
col would necessitate acquiring far more measurements, requiring
each participant to spend many hours exercising at steady state.
Our study used a relatively high heart rate. If a future studywere to
be designed with a lower heart rate, our previous work suggests it
would likely show smaller effects.12 However, our present study
was designed to distinguish, with statistical validity within individual
patients, small differences in haemodynamic response between pro-
tocols for adjusting VV delay. To achieve this level of precision
required maximizing signal-to-noise ratio, which we know requires
elevated heart rate.12 At lower heart rates if the effect size were
half as large, each patient would have to undergo a protocol four
times as longer to obtain a result with the same precision.
Our patients were an unselected sample of patients with CRT at
our centre. The majority had underlying left bundle branch block
(LBBB), while a few had underlying right bundle branch block
(RBBB) or complete heart block.Wedid not set out to test for differ-
ences between, for example, LBBB and RBBB, which would require
many more patients to undergo the experiment. Instead we show
all the data for all the patients, indicating the native conduction
pattern of each. Informally, patients of all patterns appear to have
similar shapes to their results. Based on this, any future study
seeking to exclude a difference between LBBB and RBBB would
have to have a very large sample size, of hundreds of patients, in
order to be able to exclude a difference of a size that might have
gone unobserved in our study.
Our study does not have any data on mechanical dyssynchrony.
This is because we do not test for this in our patients any more.
We have previously observed that in our hands mechanical dyssyn-
chrony measurements do not have sufficient test–retest reproduci-
bility underblindedconditions tobeusefully26,28 tested as apredictor
of anything else.
Our study did not attempt the larger task of addressing whether
optimal AV delay varies at different VV delays, because this would
extend the duration of data acquisition from about 3 h per patient
to 9 h. Our study does suggest that setting VV delays other than
zero is not generally helpful at any AV delay. Therefore, a practical
approach might be to fix VV delay at zero and then optimize
AV delay.
Clinical implications
Aside from themechanistic implications, our study suggests that clin-
ical CRT optimization might use resources best by focusing on AV
delay and leavingVVdelay set at zero. It is also a reminder that reliable
(i.e. reproducible) optimization requires efforts to ensure that the
subtle signal of between-setting differences is not obscured by spon-
taneous beat-to-beat biological variability.
Conclusion
The apparent size of the effect of VV delay adjustment is crucially
dependent on the convention used to keep AV delay apparently
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constant. If constancy of AV delay means fixing the time to first ven-
tricular lead, then VV delay adjustment (i.e. delaying the second lead)
has little or no effect.
If, in contrast, AV delay is defined as the time to a particular ven-
tricular lead (left or right), then the effect of VV delay adjustment
can be large and adverse, particularly if making the other lead earlier.
However, viewed from the other convention this large effect of
pacing the ‘variable’ lead earlier might be argued to be simply a mani-
festation of un-noticed shortening of AV delay.
In practice it may be pragmatic as well as physiological to leave VV
delay at zero, after AV delay is optimized. In our cohort, we found no
sign that changing VV delay away from zero improves physiology,
despite using large numbers of replicate measurements which
might (with present routine techniques) be clinically impractical.
To avoid unnecessary appearance of conflict, future reports of VV
optimizationmight usefully specifywhich aspect of AVdelaywas kept
constant, along with individual-patient assessments of precision.
Supplementary material
Supplementary material is available at Europace online.
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